Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Eidos Therapeutics, Inc.
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Eidos Therapeutics, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Eidos Therapeutics, Inc. since 2005.
The reporting company's ticker symbol is EIDX. The reporting company's CIK number is 1731831.
The total value of stock buying since 2005 is $129,589,926.
The total value of stock sales since 2005 is $1,102,471.
The total value of stock option exercises since 2005 is $0.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2018-12-07||Bridgebio Pharma Llc (10% Owner)||Sale||41,174||14.15||582,612|
|2018-12-06||Bridgebio Pharma Llc (10% Owner)||Sale||38,970||13.34||519,859|
|2018-12-05||Bridgebio Pharma Llc (10% Owner)||Buy||1,103,848||14.01||15,464,910|
|2018-12-03||Bridgebio Pharma Llc (10% Owner)||Buy||1,750,000||15.50||27,125,000|
|2018-06-22||Bridgebio Pharma Llc (10% Owner)||Buy||1,000,000||17.00||17,000,000|
|2018-06-22||Kumar Neil (Chief Executive Officer)||Buy||1,000,000||17.00||17,000,000|
|2018-06-22||Satvat Ali J. (Director)||Buy||1,000,000||17.00||17,000,000|
|2018-06-22||Shah Rajeev M. (Director)||Buy||1,058,824||17.00||18,000,008|
Insider trading activities including stock purchases, stock sales, and option exercises of EIDX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Eidos Therapeutics, Inc. (symbol EIDX, CIK number 1731831) see the Securities and Exchange Commission (SEC) website.